Consun Pharmaceutical Group announced its annual results for the year ended December 31, 2025. The group recorded revenue of RMB 3.417 billion, an increase of 15.17% compared to the previous year. Profit attributable to equity shareholders was RMB 1.078 billion, up 18.41% year-on-year. Basic earnings per share were RMB 1.27, and the board proposed a final dividend of HK$0.4 per share.

Sales revenue from renal drugs reached approximately RMB 2.40 billion in 2025, representing a year-on-year growth of about 20.3%, maintaining its leading position in the modern Chinese patent medicine category for kidney disease. Key progress was made in the serialization of renal products: Roxadustat Capsules and Empagliflozin Tablets were successively approved for market launch, further enriching the product portfolio. Academic influence continued to grow: Niaoduqing Granules were featured in the 2025 "Clinical Guidelines for Niaoduqing in Treating Chronic Kidney Disease" and the 2025 "Clinical Guidelines for Integrated Chinese and Western Medicine in Preventing and Treating Stages 1-3 CKD." Yishen Huashi Granules published multiple research papers in international journals such as the Journal of Ethnopharmacology and Frontiers in Pharmacology and were approved as a National Secondary Protected Traditional Chinese Medicine variety with a seven-year protection period. Multi-dimensional medical research provided solid evidence for product access and clinical application, helping to steadily expand market share. The overseas expansion of Niaoduqing Granules was also effective, successfully entering the Indonesian market and appearing on local academic platforms.

Sales revenue from medical imaging contrast agents was approximately RMB 188 million in 2025, a year-on-year increase of 10.9%. Centered around the "One Gadolinium, Three Iodine" product layout, the group focused on core customer academic needs, further enhancing its academic promotion capabilities through two models: medically service-driven academic programs and research innovation-driven medical projects. Throughout the year, nearly 300 thematic academic programs, such as "Chenxin Contrast" and "Chenying Chenxiang," were conducted, along with nearly 20 clinical medical research projects. Innovative activities like "Rewarded Case Interactions" and "Expert Book Signings" were launched, significantly boosting academic influence and brand value. In June 2025, Gadopentetate Dimeglumine Injection was selected as the first-choice product in the Xinjiang 26-province alliance centralized procurement, further consolidating the company's market position in this segment.

Sales revenue from women's and children's drugs was RMB 376 million in 2025, a year-on-year increase of approximately 4.0%. Although growth was temporarily affected by market conditions, its strategic value as an important profit growth driver for the group continued to be highlighted. The women's and children's team used "academic leadership + scientific marketing" as its engine to build a full-chain academic ecosystem encompassing "case collection - knowledge accumulation - guideline leadership - digital upgrade." It actively promoted the revision of the "Guidelines for the Prevention and Treatment of Iron Deficiency and Iron Deficiency Anemia During Pregnancy" to improve diagnosis and treatment standards. The team assisted in compiling the "China Obstetrics Case Database" and "Analysis of Complex Obstetric Cases," selecting over 300 high-quality cases in the first phase to promote the integration and sharing of obstetric knowledge. Throughout the year, the team exclusively supported 51 sessions of the "Classic Obstetric Cases Competition," with the influence of high-quality brand activities continuing to rise, and the team's professional capabilities and personnel efficiency significantly improved.